Polydex Pharmaceuticals Limited and BioSpectra Inc. Announce Business Combination

Written by Customer Service on . Posted in Mergers And Acquisitions.

TORONTO, Aug. 09, 2023 (GLOBE NEWSWIRE) — Polydex Pharmaceuticals Limited (OTC Pink: POLXF) (the “Company” or “Polydex”) announced today that it has consummated the Plan of Arrangement (the “Arrangement”) whereby BioSpectra, Inc. and BioSpectra Canada, Ltd (together, “BioSpectra”) acquired all of the outstanding common and preferred shares of the Company for total consideration of $6,940,000, of which US$6,924,980.02 was paid for 3,432,478 common shares outstanding and US$15,019.98 was paid for 899,400 Class B Preferred shares outstanding. The price per common share was US$2.017.

The Arrangement was effected pursuant to a statutory plan of arrangement (the “Arrangement”) under section 182 of the Ontario Business Corporations Act (the “OBCA”). The Arrangement resulted in each issued and outstanding share of Polydex being deemed transferred to BioSpectra by each Polydex shareholder, without any further act or formality on the part of the Polydex shareholder. Each Polydex shareholder as of the effective time of the Arrangement will receive consideration in exchange for their shares. Polydex shares were de-listed as of the close of trading on August 7, 2023.

Polydex, based in Toronto, Ontario, is engaged in the manufacturing of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry and also the development, manufacturing and marketing of biotechnology-based products for the human pharmaceutical market. The Company focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate and other specialty chemicals. The Company conducts its business operations through its two wholly-owned subsidiaries/divisions. The manufacture and sale of Dextran and derivative products is conducted through Dextran Products and Chemdex Inc. which is incorporated in the State of Kansas, United States.

Contact:
George Usher: GU-dextran@rogers.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.